Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferachel Forte is an oral multi-ingredient nutraceutical formulation primarily indicated for the management of iron deficiency anemia (IDA), particularly in specialized populations such as those with chronic kidney disease (CKD). Developed by Laborest (Uriach), the product features ferric sodium EDTA (sodium feredetate) as its core iron source. Ferric sodium EDTA is a stable chelate that prevents iron from reacting with dietary inhibitors in the gastrointestinal tract, thereby enhancing bioavailability and minimizing common side effects like gastric irritation. The formulation is further enriched with vitamin C to promote iron absorption, folic acid to support erythropoiesis, and essential trace elements including copper, zinc, and selenium, which act as enzymatic cofactors and antioxidants. Clinical evidence suggests that Ferachel Forte not only improves iron status and hemoglobin levels but also helps modulate systemic inflammation by reducing C-reactive protein and hepcidin levels, which are often elevated in CKD-related functional iron deficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ferachel Forte.